U.S. Markets open in 7 hrs 5 mins

argenx SE (ARGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
286.82+5.23 (+1.86%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close281.59
Open284.68
Bid285.97 x 800
Ask286.73 x 900
Day's Range282.96 - 288.55
52 Week Range103.75 - 288.55
Volume250,212
Avg. Volume167,444
Market Cap13.431B
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High
    Investor's Business Daily

    Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High

    Halozyme Therapeutics boosted its EPS and sales guidance for the year, buoyed by partnerships with big drugmakers such as Roche and Johnson & Johnson, sparking HALO stock to a record high.

  • Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises
    Zacks

    Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises

    Halozyme (HALO) reports better-than-expected third-quarter results. The company raises outlook for the year anticipating higher royalties.

  • Benzinga

    Recap: argenx Q3 Earnings

    Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were down 450.00% year over year to ($3.96), which missed the estimate of ($2.81).Revenue of $8,968,000 declined by 5.78% year over year, which missed the estimate of $16,850,000.Guidance argenx hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Oct 22, 2020View more earnings on ARGXTime: 08:30 AMET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.argenx.com%2F&eventid=2738263&sessionid=1&key=F469E4B3D87911A523DAB8276C85E03C®Tag=&sourcepage=registerRecent Stock Performance 52-week high: $284.0052-week low: $103.75Price action over last quarter: Up 4.79%Company Profile argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Earnings Scheduled For October 22, 2020 * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.